148 related articles for article (PubMed ID: 36933140)
1. Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer's Disease.
Morin PJ; Zhang Q; Xia W; Miller D; Querfurth H; Tahami Monfared AA
Neurol Ther; 2023 Jun; 12(3):721-726. PubMed ID: 36933140
[TBL] [Abstract][Full Text] [Related]
2. How donanemab data address the coverage with evidence development questions.
Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
[TBL] [Abstract][Full Text] [Related]
3. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.
Brockmann R; Nixon J; Love BL; Yunusa I
Lancet Reg Health Am; 2023 Apr; 20():100467. PubMed ID: 36908502
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the First Round of Public Comments for the National Coverage Determination for Monoclonal Antibodies in the Treatment of Alzheimer's Disease.
Wahl J; Gadbois EA
J Aging Soc Policy; 2023 Jul; ():1-20. PubMed ID: 37486161
[TBL] [Abstract][Full Text] [Related]
5. A Roadmap for Improving Medicare's Application of Coverage With Evidence Development.
Lakdawalla D; Tunis S; Neumann P; Whicher D; Zeitler E; Liden B
Value Health; 2024 May; ():. PubMed ID: 38795958
[TBL] [Abstract][Full Text] [Related]
6. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
7. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.
Bateman RJ; Cummings J; Schobel S; Salloway S; Vellas B; Boada M; Black SE; Blennow K; Fontoura P; Klein G; Assunção SS; Smith J; Doody RS
Alzheimers Res Ther; 2022 Nov; 14(1):178. PubMed ID: 36447240
[TBL] [Abstract][Full Text] [Related]
8. Statement from The Memory and Aging Program at Butler Hospital on CMS National Coverage Determination for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease.
R I Med J (2013); 2022 May; 105(4):75. PubMed ID: 35476744
[No Abstract] [Full Text] [Related]
9. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
[TBL] [Abstract][Full Text] [Related]
10. Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome.
Hillerstrom H; Fisher R; Janicki MP; Chicoine B; Christian BT; Esbensen A; Esralew L; Fortea J; Hartley S; Hassenstab J; Keller SM; Krinsky-McHale S; Lai F; Levin J; McCarron M; McDade E; Rebillat AS; Rosas HD; Silverman W; Strydom A; Zaman SH; Zetterberg H
Alzheimers Dement; 2024 May; 20(5):3649-3656. PubMed ID: 38480678
[TBL] [Abstract][Full Text] [Related]
11. Coverage with evidence development: where are we now?
Zeitler EP; Gilstrap LG; Coylewright M; Slotwiner DJ; Colla CH; Al-Khatib SM
Am J Manag Care; 2022 Aug; 28(8):382-389. PubMed ID: 35981123
[TBL] [Abstract][Full Text] [Related]
12. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
[TBL] [Abstract][Full Text] [Related]
13. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
Gauthier S; Leuzy A; Racine E; Rosa-Neto P
Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
[TBL] [Abstract][Full Text] [Related]
15. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
Rygiel K
Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
[TBL] [Abstract][Full Text] [Related]
16. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
17. CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY.
Chambers JD; Chenoweth MD; Pyo J; Cangelosi MJ; Neumann PJ
Int J Technol Assess Health Care; 2015 Jan; 31(5):347-54. PubMed ID: 26750558
[TBL] [Abstract][Full Text] [Related]
18. How changes in the Medicare coverage process have facilitated the spread of new technologies.
Straube BM
Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-314-W5-316. PubMed ID: 15975989
[TBL] [Abstract][Full Text] [Related]
19. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
Shi M; Chu F; Zhu F; Zhu J
Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
